Among anticancer strategies, therapeutic inhibitors targeting immune checkpoints such as CTLA-4, PD-1, and PD-L1 have shown efficacy in a proportion of cancer patients by unleashing an adaptive antitumor immune response (13). The gene discussed is CD274; the disease is cancer.